TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Physician expectations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physician definition of success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of active learning among teachers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Implementation Fidelity
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Student Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back pain intensity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability level of low back pain patients
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Deep clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of atrial scar by voltage mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of atrial scar by impedance mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of atrial scar by gadolinium enhanced MR imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum Cytokines (TNF-α, IL-2, IL-6, IL-8, IL-1β, MCP-1, MIP-1β, MIP-1α, IFN-γ, and IL-12p70)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute blood levels of total AAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prostate-Specific antigen level ≥ 50% (PSA50) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival (PFS) by RECIST version 1.1
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in the number of treated VT episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of treatment related serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mid-buccal soft tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid-crestal soft tissue height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Symptom Control Change from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drooling amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multidimensional Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Muscular Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Efficiency on bowel symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Psychological assessment of Alexithymia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological assessment of caregiver's burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Assessment of patient and caregiver self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychological assessment of patient's burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Elongation Index (Deformability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Critical Shear Stress (Aggregation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bone gain evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Biocompatibility evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Products of lipoperoxidation (LPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nitric Oxide (NO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychiatric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GFR measured by radionuclide method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: GFR measured by creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: levels and patterns of immune infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: histopathological growth patterns of liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: efficacy of various treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serebral biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perinatal outcome
Endpoint domain: Mortality/survival
Primary endpoint: ECG algorithm performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of surgery for hemodialysis arteriovenous access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Marx activity rating scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee stability in sports/cutting-pivoting ability scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms of depression and anxiety at the end of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in symptoms of depression and anxiety at follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional performance tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of participants with HIV-1 RNA < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: satisfaction of needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Drug Exposure (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum peak observed plasma inclisiran concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (time to reach maximum peak plasma inclisiran concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 (elimination half-life of inclisiran)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in PCSK9 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in LDL-C from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of development of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Titer of specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT on day 21 after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinically significant deviations from vital functions and laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of investigational rescue therapies
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of administering therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of cholangitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recommended Phase 2 dose (RP2D) finding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CAR positive T cells and CAR transgene levels in peripheral blood and bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of progression
Endpoint domain: Mortality/survival
Primary endpoint: Changes in maternal oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications of pregnancy: gestational diabetes mellitus
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving PASI 75 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recommended testing proportion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MSOT signal for hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Feasibility of the adapted intervention - Observed length of recruitment time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of the adapted intervention - Observed retention rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Testing negative for SARS-CoV-2 by RT-PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: COVID-19 symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual dexterity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Device/Procedure Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain status
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Combined Fistula Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in post stroke pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in walking speed from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite pain, anxiety, and well-being score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kellgren-Lawrence scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in mean serum phosphorus level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concussion-Related Beliefs Change Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concussion-Related Attitudes Change Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HRqOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual analogue scale (VAS score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Japanese Orthopaedic Association Score--Low Back Pain (JOA Low Back Pain Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentration of Tralokinumab in lesional skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyspnea 12 scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Beck anxiety scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spiritual Well-Being Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete resection rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adenoma recurrence rate (ARR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with hyperkalemia events
Endpoint domain: Adverse events/effects
Primary endpoint: Initiation rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Per protocol completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of complete pathological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reporting adverse events of Grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Metacognitive Awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Binary reading of renal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Histological classification of operated renal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Glottic exposure grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAWP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: At least 5% body weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle Activation Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of subjects with Dose-Limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Breathing effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 2-Hour Difference in Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin Sensitivity (by Oral Minimal Model)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2-hour Incremental Area Under the Curve (iAUC) for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Timing of beta bursts in motor cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spatial location of beta bursts in motor cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Screen failure rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention rate/Acceptability
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PSMA PET metastasis free survival (ppMFS)
Endpoint domain: Mortality/survival
Primary endpoint: quality of life (sexual subdomain)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: quality of life (hormonal subdomain)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: University of Pennsylvania Smell Identification Test (UPSIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in clinical laboratory results - Cerebrospinal fluid (CSF) White Blood Cell (WBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in clinical laboratory results - Cerebrospinal fluid (CSF) protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in baseline in structural MRI assessing new abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage change from baseline in geometric means of CSF mHTT protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Survival at ICU discharge
Endpoint domain: Mortality/survival
Primary endpoint: Ritvo-Freeman Real Life Scale (RFRLS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parental Stress Index (PSI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Management of arterial embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sequelae
Endpoint domain: Adverse events/effects
Primary endpoint: change of taste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intensity of post-concussion symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of updated COVID-19 vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of bezuclastinib at the selected dose versus placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of bezuclastinib as assessed by number of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Knee balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days with supplementary oxygen therapy and/or mechanical ventilation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decrease in 24-h Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with a PHQ-9 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of discrepancies and agreements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Phosphorylation of STAT-3 in MDSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in health status after using the application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean value change from baseline to day 27
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Moderate or Severe headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with abnormal laboratory tests results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with abnormal technical exam results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microbial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Amplitude of rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Pain Intensity Differences in Pain Score from baseline Over 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shift in mean gut microbiota diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean quantitative mobility and leg function performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in mean quantitative maximal oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Particle Count Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Thrombus Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average number of bradykinin-mediated angioedema attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ankle mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Surgical complete resection rate (R0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nursing Care Scale for Dying Patients and Their Families
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nurse's Difficulty Scale for Dying Patients and Their Families
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ingestive behavior constructs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of hemorrhagic complication
Endpoint domain: Adverse events/effects
Primary endpoint: Health inequalities
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of service utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Vocal analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Solicited Local Adverse Events at 7 Days Post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Solicited Systemic Adverse Events at 7 Days Post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Serious Adverse Events Related to Study Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Phenylalanine indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Health Questionnaire -15 (PHQ-15)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Numeric Rating Scales according to EURONET-SOMA
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Participants with Intervention-emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects